Stock Track | Enliven Therapeutics Soars 5.35% on Positive Clinical Data, Analyst Initiation, and Earnings Beat

Stock Track

May 12

Enliven Therapeutics' stock soared 5.35% during intraday trading on Tuesday, driven by a confluence of positive developments for the biotechnology company.

The surge follows the announcement of additional positive Phase 1 clinical trial data for its drug candidate ELVN-001 in chronic myeloid leukemia (CML), which is scheduled for an oral presentation at the upcoming EHA 2026 congress. The updated results show continued meaningful anti-disease activity and a favorable safety profile in a heavily pretreated patient population.

Further bolstering investor sentiment, Guggenheim initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $80. This positive analyst action was highlighted in a broader research roundup. Additionally, the company recently reported quarterly results that beat Wall Street expectations, posting a loss per share of $0.38 compared to the estimated loss of $0.46.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1150376332"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150376332\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150376332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 23:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150376332","market":"nz","top_or_hot":-1,"title":"Stock Track | Enliven Therapeutics Soars 5.35% on Positive Clinical Data, Analyst Initiation, and Earnings Beat","media":"Stock Track","content":"<p>Enliven Therapeutics' stock soared 5.35% during intraday trading on Tuesday, driven by a confluence of positive developments for the biotechnology company.</p><p>The surge follows the announcement of additional positive Phase 1 clinical trial data for its drug candidate ELVN-001 in chronic myeloid leukemia (CML), which is scheduled for an oral presentation at the upcoming EHA 2026 congress. The updated results show continued meaningful anti-disease activity and a favorable safety profile in a heavily pretreated patient population.</p><p>Further bolstering investor sentiment, Guggenheim initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $80. This positive analyst action was highlighted in a broader research roundup. Additionally, the company recently reported quarterly results that beat Wall Street expectations, posting a loss per share of $0.38 compared to the estimated loss of $0.46.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Enliven Therapeutics Soars 5.35% on Positive Clinical Data, Analyst Initiation, and Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Enliven Therapeutics Soars 5.35% on Positive Clinical Data, Analyst Initiation, and Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Enliven Therapeutics' stock soared 5.35% during intraday trading on Tuesday, driven by a confluence of positive developments for the biotechnology company.</p><p>The surge follows the announcement of additional positive Phase 1 clinical trial data for its drug candidate ELVN-001 in chronic myeloid leukemia (CML), which is scheduled for an oral presentation at the upcoming EHA 2026 congress. The updated results show continued meaningful anti-disease activity and a favorable safety profile in a heavily pretreated patient population.</p><p>Further bolstering investor sentiment, Guggenheim initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $80. This positive analyst action was highlighted in a broader research roundup. Additionally, the company recently reported quarterly results that beat Wall Street expectations, posting a loss per share of $0.38 compared to the estimated loss of $0.46.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELVN","symbol_name":"Enliven Treateutics","start_time":0,"source_url":"","article_id":"1150376332","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150376332","pubTimestamp":1778598546,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Enliven Therapeutics' stock soared 5.35% during intraday trading on Tuesday, driven by a confluence of positive developments for the biotechnology company.The surge follows the announcement of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELVN":"Enliven Treateutics"},"translate_title":"股票追踪|Enliven Therapeutics因积极的临床数据、分析师发起和盈利超出预期而飙升5.35%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELVN":1},"content_text":"Enliven Therapeutics' stock soared 5.35% during intraday trading on Tuesday, driven by a confluence of positive developments for the biotechnology company.The surge follows the announcement of additional positive Phase 1 clinical trial data for its drug candidate ELVN-001 in chronic myeloid leukemia (CML), which is scheduled for an oral presentation at the upcoming EHA 2026 congress. The updated results show continued meaningful anti-disease activity and a favorable safety profile in a heavily pretreated patient population.Further bolstering investor sentiment, Guggenheim initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $80. This positive analyst action was highlighted in a broader research roundup. Additionally, the company recently reported quarterly results that beat Wall Street expectations, posting a loss per share of $0.38 compared to the estimated loss of $0.46.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}